Enorama Pharma AB (publ) (ERMA.ST)

SEK 2.95

(3.15%)

Total Assets Summary of Enorama Pharma AB (publ)

Enorama Pharma AB (publ)'s latest annual total assets in 2023 was 34.38 Million SEK , down -29.42% from previous year.
Enorama Pharma AB (publ)'s latest quarterly total assets in 2024 Q1 was 36.96 Million SEK , up 7.49% from previous quarter.
Enorama Pharma AB (publ) reported annual total assets of 48.72 Million SEK in 2022, down -4.34% from previous year.
Enorama Pharma AB (publ) reported annual total assets of 50.93 Million SEK in 2021, up 24.52% from previous year.
Enorama Pharma AB (publ) reported quarterly total assets of 36.96 Million SEK for 2024 Q1, up 7.49% from previous quarter.
Enorama Pharma AB (publ) reported quarterly total assets of 34.38 Million SEK for 2023 FY, down -29.42% from previous quarter.

Annual Total Assets Chart of Enorama Pharma AB (publ) (2023 - 2014)

Historical Annual Total Assets of Enorama Pharma AB (publ) (2023 - 2014)

Year	Total Assets	Total Assets Growth
2023	34.38 Million SEK	-29.42%
2022	48.72 Million SEK	-4.34%
2021	50.93 Million SEK	24.52%
2020	40.9 Million SEK	-3.94%
2019	42.58 Million SEK	9.67%
2018	38.83 Million SEK	150.72%
2017	15.48 Million SEK	13.66%
2016	13.62 Million SEK	48.63%
2015	9.16 Million SEK	148.19%
2014	3.69 Million SEK	0.0%

Year	Total Assets	Total Assets Growth
2024 Q2	49.71 Million SEK	34.52%
2024 Q1	36.96 Million SEK	7.49%
2023 FY	34.38 Million SEK	-29.42%
2023 Q3	37.26 Million SEK	11.63%
2023 Q4	34.38 Million SEK	-7.72%
2023 Q2	33.38 Million SEK	-7.17%
2023 Q1	35.96 Million SEK	-26.19%
2022 FY	48.72 Million SEK	-4.34%
2022 Q4	48.72 Million SEK	15.04%
2022 Q3	42.35 Million SEK	-21.31%
2022 Q2	53.82 Million SEK	24.69%
2022 Q1	43.16 Million SEK	-15.25%
2021 Q2	42.7 Million SEK	-11.84%
2021 Q1	48.44 Million SEK	18.43%
2021 Q4	50.93 Million SEK	21.21%
2021 Q3	42.02 Million SEK	-1.6%
2021 FY	50.93 Million SEK	24.52%
2020 Q1	36.03 Million SEK	-15.39%
2020 Q4	40.9 Million SEK	8.59%
2020 Q3	37.67 Million SEK	-0.59%
2020 Q2	37.89 Million SEK	5.17%
2020 FY	40.9 Million SEK	-3.94%
2019 Q4	42.58 Million SEK	25.16%
2019 Q3	34.02 Million SEK	21.33%
2019 Q2	28.04 Million SEK	3.28%
2019 Q1	27.15 Million SEK	-30.07%
2019 FY	42.58 Million SEK	9.67%
2018 Q3	19.26 Million SEK	-17.24%
2018 Q2	23.27 Million SEK	14.93%
2018 FY	38.83 Million SEK	150.72%
2018 Q4	38.83 Million SEK	101.55%
2018 Q1	20.25 Million SEK	30.78%
2017 Q4	15.48 Million SEK	4.48%
2017 Q2	17.42 Million SEK	43.4%
2017 Q1	12.15 Million SEK	-10.83%
2017 FY	15.48 Million SEK	13.66%
2017 Q3	14.82 Million SEK	-14.92%
2016 FY	13.62 Million SEK	48.63%
2016 Q2	19.27 Million SEK	211.66%
2016 Q4	13.62 Million SEK	-16.11%
2016 Q1	6.18 Million SEK	-32.53%
2016 Q3	16.24 Million SEK	-15.75%
2015 Q4	9.16 Million SEK	0.0%
2015 Q1	- SEK	0.0%
2015 FY	9.16 Million SEK	148.19%
2014 FY	3.69 Million SEK	0.0%

Peer Total Assets Comparison of Enorama Pharma AB (publ)

Name	Total Assets	Total Assets Difference
AcuCort AB	58.5 Million SEK	41.229%
AlzeCure Pharma AB (publ)	32 Million SEK	-7.45%
BioGaia AB (publ)	2.33 Billion SEK	98.526%
Enzymatica AB (publ)	125.91 Million SEK	72.691%
Gabather AB (publ)	2.93 Million SEK	-1070.752%
Klaria Pharma Holding AB (publ.)	73.12 Million SEK	52.975%
Moberg Pharma AB (publ)	634.73 Million SEK	94.583%
Nanexa AB (publ)	132.25 Million SEK	74.001%
Newbury Pharmaceuticals AB (publ)	90.87 Million SEK	62.161%
ODI Pharma AB	12.27 Million SEK	-180.122%
Orexo AB (publ)	786.6 Million SEK	95.629%
Probi AB (publ)	1.55 Billion SEK	97.782%
Swedencare AB (publ)	9.52 Billion SEK	99.639%
Swedish Orphan Biovitrum AB (publ)	74.02 Billion SEK	99.954%
Toleranzia AB	160.42 Million SEK	78.567%
Vivesto AB	355.87 Million SEK	90.338%